Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Semin Cancer Biol. 2020 Feb 7;68:209–229. doi: 10.1016/j.semcancer.2020.02.003

Figure 3. Off-target based drug repurposing initiatives for dasatinib and ibrutinib in various cancers.

Figure 3.

A. Repurposing of the dual SRC/ABL inhibitor, developed to treat CML, for various B cell malignancies and NSCLC due to its ability to also inhibit BTK and EGFR (weak), respectively. Combination therapy with the potent EGFR TKI erlotinib led to the identification of mutant DDR2 as a novel cancer driver in LUSQ. B. Repurposing of the irreversible BTK inhibitor ibrutinib, developed to treat different B cell malignancies, for breast cancer (with trastuzumab) and EGFR-mutant NSCLC due to its ability to also inhibit HER2 and EGFR, respectively. * indicates oncogenic mutation; ** indicates gene amplification; light bulb indicates discovery of new drug-protein interaction.